-
Mashup Score: 0
Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers, the benefits SCINTIX technology can provide for these patients, and how John Theurer Cancer Center plans to use this technology to improve patient outcomes and support further radiation therapy research.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC - 1 year(s) ago
Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Part B of the phase 2 DeFianCe seeks to build on earlier positive results with second-line DKN-01 plus bevacizumab and chemotherapy from part A of the study in advanced CRC. #crcsm #oncology https://t.co/bIcpcuFzvm https://t.co/Jn1kuJP6Jn
-
-
Mashup Score: 0
Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial. @DanaFarber #oncology https://t.co/0ZJSKhaaJy
-
-
Mashup Score: 0
Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Single-agent and/or combination immunotherapy approaches continue to reign supreme in the treatment of patients with endometrial cancer; recent trials have reinforced their role in the first and second lines. @uamscancer #OncLiveIPC #gyncsm https://t.co/oJCOLTevgW https://t.co/2i6do3y695
-
-
Mashup Score: 0LOTIS-9 Trial of Loncastuximab Tesirine/Rituximab in Untreated DLBCL Pauses Enrollment - 1 year(s) ago
ADC Therapeutics has voluntarily paused enrollment to the phase 2 LOTIS-9 trial investigating the combination of loncastuximab tesirine and rituximab for use in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ADC Therapeutics has voluntarily paused enrollment to the phase 2 LOTIS-9 trial investigating loncastuximab tesirine and rituximab for use in unfit or frail patients with previously untreated DLBCL. #lymsm #oncology https://t.co/24J3ezBlEl
-
-
Mashup Score: 0
Adnan F. Danish, MD, discusses the use of novel radiotherapy approaches in cancer care.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Adnan F. Danish, MD, of @JTCancerCenter, discusses the use of novel radiotherapy approaches in cancer care. #oncology #medtwitter https://t.co/LCgJVy50NJ
-
-
Mashup Score: 0Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management - 1 year(s) ago
Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode of #OncLiveOnAir, @lymphomaphilia & Jeremy Abramson, MD, discuss treatment options for patients with LBCL following relapse on their initial therapies & challenges that arise in clinical trials vs in the real-world setting. #lymsm https://t.co/9EUlkybeQl https://t.co/nr1GmETcuU
-
-
Mashup Score: 1
Enhanced antitumor activity was shown with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early findings from the phase 1 LuPARP study show that olaparib plus the radioligand lutetium Lu 177 vipivotide tetraxetan produced a PSA response rate of at least 50% in 66% of patients with mCRPC. @SandhuShahneen @PeterMacCC #pcsm https://t.co/y2RO7jB0LG https://t.co/LBTvn4xzEn
-
-
Mashup Score: 0Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial - 1 year(s) ago
Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Claire Harrison, MD, of @GSTTnhs, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera. #oncology https://t.co/NY487rgJOP https://t.co/BdZhkw3PXY
-
-
Mashup Score: 0
Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting @jasonlukemd @UPMCHillmanCC #melsm #ASCO23 https://t.co/cQjf4UJFWf
-
Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers and the benefits SCINTIX technology can provide for these patients. @HMHNewJersey @sjh_nj #lcsm #oncology https://t.co/riGigKU1Jz